LifeCycle Pharma Achieved Strong Progress in its Pipeline - Positive Results in the Phase 2 extension study for LCP-AtorFen as well as in Phase 2 for LCP-TacroTM in de novo kidney patients
14-05-09 kl. 14/5 2009 09:00 | Veloxis Pharmaceuticals 0,90 (+4,65%)
Se flere nyheder om Veloxis Pharmaceuticals
Positive Results in the Phase 2 extension study for LCP-AtorFen as well as in Phase 2 for LCP-TacroTM in de novo kidney patients. See more in attached PDF. 
English PDF
Der er endnu ikke skrevet nogen kommentarer til denne artikel.
Skriv en kommentarer til denne artikel:
Send kommentar
Skriv en kommentarer til denne artikel:
Send kommentar
| PRIS | 0,90 |
|---|---|
| ÆNDRING | +0,04 (+4,65%) |
| ÅBEN | 0,87 |
| SIDSTE LUK | 0,86 |
| DEBAT | - |
 |
